Related Tags >> acomplia FDA EMEA Chris Viehbacher

Sanofi-Aventis News

Most Popular Sanofi-Aventis Story

Sanofi discontinues clinical trials for Acomplia

November 5, 2008 — 12:54pm ET | By John Carroll

Sanofi-Aventis is discontinuing all ongoing clinical trials for its obesity treatment Acomplia. The pharma giant said it was prompted to halt the trials after the European Medicines Agency concluded... Read more...

Sanofi-Aventis Press Releases

Sanofi-Aventis Pharma S.A. Withdraws Application For An Extension Ofindication For Taxotere And Docetaxel Winthrop (docetaxel)
FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
ImmunoGen, Inc. Earns $4 Million Milestone Payment with Sanofi-Aventis (France)'s Initiation of a Phase II Trial with AVE1642
Sanofi-aventis is Complying With the EMEA's Recommendation to Temporarily Suspend the Marketing Authorisation of Acomplia(R) in
EU Drugs Regulator Recommends Suspension Of Sanofi's Acomplia

Latest Headlines

Sanofi discontinues clinical trials for Acomplia
November 5, 2008
Analysts: Look for shake-up at Sanofi
November 3, 2008
Sanofi-Aventis expands its R&D work in China
October 22, 2008
Sanofi-Aventis - Biotech Market Share Report
September 28, 2008
GSK's Viehbacher picked as Sanofi CEO
September 10, 2008
Sanofi-Aventis scores positive data in Multaq trial
September 3, 2008
Regeneron licenses tech to Sanofi in $21.5M deal
August 5, 2008
Acambis shares soar on $548M buyout deal
July 28, 2008
4. Sanofi-Aventis - Top 15 R&D Budgets
November 28, 2007
Big Pharma takes an interest in cancer vaccines
September 19, 2007
Sanofi signs stem cell pact in China
September 14, 2007
4. Sanofi-Aventis and Oxford BioMedica
September 11, 2007

Paid Research Reports